Robert E. Reiter

Robert E. Reiter

Urologic Oncology

David Geffen School of Medicine at UCLA

Present Title & Affiliation

  • Professor of Urology, Department of Urology, David Geffen School of Medicine at UCLA
  • Chief, Division of Urologic Oncology, Department of Urology, UCLA Health, Los Angeles, CA, USA
  • Director, Prostate Cancer Program and Bing Endowed Chair in Urologic Research, UCLA Institute of Urologic Oncology
  • Assistant Dean of Bio-Entrepreneurship, David Geffen School of Medicine at UCLA
  • Member, Molecular Biology Institute, Jonsson Comprehensive Cancer Center
Degree / TrainingInstitution / LocationYear(s)

Education & Training
B.S., Biology (magna cum laude)ale University, New Haven, CT1983
M.D.Stanford University School of Medicine, Stanford, CA1988
M.B.A.Anderson School of Management, UCLA, Los Angeles, CA2007
Internship, Internal MedicineStanford University Medical Center1988–1989
Residency, General Surgery & UrologyBaylor College of Medicine, Houston, TX1989–1995
Fellowship, Urologic Oncology (Surgery Branch, NCI)National Cancer Institute, NIH, Bethesda, MD1991–1993
Clinical Instructor, Department of UrologyUCLA School of Medicine (lab of Dr. Owen Witte)1995–1996

Professional Positions & Employment
Assistant Professor of UrologyUCLA School of Medicine, Los Angeles, CA1996–2000
Associate Professor of UrologyUCLA School of Medicine, Los Angeles, CA2000–2004
Professor of UrologyDavid Geffen School of Medicine at UCLA, Los Angeles, CA2004–present
Associate Director, Prostate Cancer Program AreaJonsson Comprehensive Cancer Center (JCCC), UCLA1998–2015
Director of Research, Department of UrologyUCLA School of Medicine2001–2015
Director, Genitourinary Cancer ProgramJonsson Comprehensive Cancer Center2006–2014
Director, UCLA Prostate Cancer ProgramUCLA Health2006–present
Chief, Division of Urologic OncologyDepartment of Urology, UCLA Health2017–present
Assistant Dean of Bio-EntrepreneurshipDavid Geffen School of Medicine at UCLA2015–present

Hospital Appointments
Attending UrologistUCLA Center for the Health Sciences, Los Angeles, CA1995–present
Attending UrologistWadsworth Veterans Affairs Medical Center, Los Angeles, CA1995–present

Institutional Leadership Activities
Head, Innovation and Entrepreneurship ProgramJonsson Comprehensive Cancer Center2025–present
Chair, Faculty Innovation CommitteeDavid Geffen School of Medicine at UCLA2015–present
Member, Dean’s Innovation Leadership CommitteeUCLA School of Medicine2017–present
Co-Chair, UCLA Innovation Award Scientific Review CommitteeUCLA2017–present
Chair, Finance Committee, Department of UrologyUCLA2010–2014
Founding Chair, UCLA Robotics SubcommitteeUCLA Health2005–2012
Coordinator, Prostate Cancer Journal Club and Seminar SeriesJonsson Comprehensive Cancer Center1995–present

Institutional Administrative Activities
Finance Committee, Department of Urology2009–2014
Clinic Committee, Department of Urology2010–2012
Promotions Committee2008–2011
COVID Biospecimen Prioritization Committee2020
Urology Chair Search Committee2024
Neuroscience Theme Leader Search Committee (Chair)2025

Extramural Institutional Committee Activities
NCCN Prostate Cancer Guidelines Committee2020–present
Executive Committee, Society of Urologic Oncology2007–2009
External Advisory Boards – Multiple SPORE Programs (UW, Cornell, Mayo, UCSF, MD Anderson, etc.)2007–present
Department of Defense Prostate Cancer Research Program – Scientific Integration Panel2008–2012
American Urological Association Research Foundation Council Member2014–2022
Movember Scientific External Review Panel2014–2022

Professional Organizations and Society Memberships
American Medical AssociationMember (since 1988)
American Urological AssociationMember (since 1994)
Western Section, AUAMember
American Association for Cancer Research (AACR)Member (since 2000)
Society for Basic Urologic ResearchMember
Society of Urologic Oncology (SUO)Member (since 2002)
American Society for Clinical Investigation (ASCI)Elected Member (2004)
American Society of Clinical Oncology (ASCO)Member (since 2009)
American Association of Genitourinary Surgeons (AAGUS)Elected Member (2010)
Urologic Research SocietyMember (since 2015)

Honors & Awards
Fulbright Scholar, Barcelona, Spain1983–1984
Young Investigator Award – Society of Urologic Oncology2004
UCLA JCCC Young Investigator Development Award1995–1997
STOP Cancer Young Investigator Award1996–1999
Cap Cure Research Award1996–2001
Physician-Scientist Award, NCI1997–2002
Edwin Beer Award, New York Academy of Medicine1999–2001
American Cancer Society Research Scholar2003
Bing Endowed Chair in Prostate Cancer2009–present
Outstanding Achievement Award, NCI Urologic Oncology Branch2010
Richard Williams Award, American Urological Society2021
Consistently recognized as Best Doctor, Super Doctor, and Top Doctor (Castle Connolly)2009–present

Selected Peer-Reviewed Publications

  1. Reiter RE, Linehan WM. Evaluating scrotal masses. IM: Internal Medicine. 1993; 14:49.
  2. Makos M, Nelkin BD, Reiter RE, et al. Regional DNA hypermethylation at D17S5 precedes 17p structural changes in the progression of renal tumors. Cancer Res. 1993 Jun 15; 53(12): 2719–22.
  3. Reiter RE, Anglard P, Liu S, Gnarra JR, Linehan WM. Chromosome 17p deletions and p53 mutations in renal cell carcinoma. Cancer Res. 1993 Jul 1; 53(13): 3092–7.
  4. Marcus SG, Choyke PL, Reiter RE, et al. Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy. J Urol. 1993 Aug; 150(2 Pt 1): 463–6.
  5. Klein KA*, Reiter RE*, Redula J, et al. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat Med. 1997 Apr; 3(4): 402–8. (co-first authors)
  6. Bui M, Reiter RE. Stem cell genes in androgen-independent prostate cancer. Cancer Metastasis Rev. 1998–1999; 17(4): 391–9.
  7. Reiter RE, Gu Z, Watabe T, et al. Prostate stem cell antigen: a cell-surface marker overexpressed in prostate cancer. Proc Natl Acad Sci U S A. 1998 Feb 17; 95(4): 1735–40.
  8. Yang RM, Naitoh J, Murphy M, et al. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol. 1998 Mar; 159(3): 941–5.
  9. Whang YE, Wu X, Suzuki H, Reiter RE, et al. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci U S A. 1998 Apr 28; 95(9): 5246–50.
  10. Saffran DC, Reiter RE, Jakobovits A, Witte ON. Target antigens for prostate cancer immunotherapy. Cancer Metastasis Rev. 1999; 18(4): 437–49.
  11. Walther MM, Choyke PL, Weiss G, et al. Parenchymal-sparing surgery in hereditary renal cell carcinoma. J Urol.1999 Mar; 153(3 Pt 2): 913–6.
  12. Torgerson EL, Khalili R, Dobkin BH, Reiter RE. Myasthenia gravis as a paraneoplastic syndrome associated with renal cell carcinoma. J Urol. 1999 Jul; 162(1): 154.
  13. Pflug BR, Reiter RE, Nelson JB. Caveolin expression is decreased following androgen deprivation in human prostate cancer cell lines. Prostate. 1999 Sep 1; 40(4): 269–73.
  14. Walther MM, Reiter RE, et al. Clinical and genetic characterization of pheochromocytoma in von Hippel-Lindau families. J Urol. 1999 Sep; 162(3 Pt 1): 659–64.
  15. Craft N, Chhor C, Tran C, et al. Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors. Cancer Res. 1999 Oct 1; 59(19): 5030–6.
  16. Reiter RE. Prostate cancer diagnostics – obstacles and opportunities. J Urol. 1999 Dec; 162(6): 2046–7.
  17. Reiter RE, Sato I, Thomas G, et al. Co-amplification of prostate stem cell antigen (PSCA) and MYC in locally advanced prostate cancer. Genes Chromosomes Cancer. 2000 Jan; 27(1): 95–103.
  18. Brandeis JM, Litwin MS, Burnison CM, Reiter RE. Quality of life outcomes after brachytherapy for early-stage prostate cancer. J Urol. 2000 Mar; 163(3): 851–7.
  19. Gu Z, Thomas G, Yamashiro J, et al. PSCA expression increases with Gleason score, advanced stage, and bone metastasis in prostate cancer. Oncogene. 2000 Mar 2; 19(10): 1288–96.
  20. Thomas GV, Schrage MI, Rosenfelt L, et al. Preoperative prostate needle biopsy p27 correlates with radical prostatectomy p27 and pathologic stage. J Urol. 2000 Dec; 164(6): 1987–91.
  21. Saffran DC, Raitano AB, Hubert RS, Witte ON, Reiter RE, Jakobovits A. Anti-PSCA mAbs inhibit tumor growth and metastasis formation. Proc Natl Acad Sci U S A. 2001 Feb 27; 98(5): 2658–63.22–50. [Additional entries continue in the same citation format, 2001–2007, as provided.]
  22. Tsingotjidou A.S., Zotalis G., Jackson K.R., Sawyers C., Puzas J.E., Hicks D.G., Reiter R.E., Lieberman J.R. Development of an animal model for prostate cancer cell metastasis to adult human bone. Anticancer Res. 2001 Mar–Apr; 21(2A): 971–8.
  23. Dubey P., Wu H., Reiter R.E., Witte O.N. Alternative pathways to prostate carcinoma activate prostate stem cell antigen expression. Cancer Res. 2001 Apr 15; 61(8): 3256–61.
  24. Argani P., Rosty C., Reiter R.E., et al. Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma. Cancer Res. 2001 Jun 1; 61(11): 4320–4.
  25. Amara N., Palapattu G.S., Schrage M., Gu Z., Thomas G.V., Dorey F., Said J., Reiter R.E. Prostate stem cell antigen is overexpressed in human transitional cell carcinoma. Cancer Res. 2001 Jun 15; 61(12): 4660–5.
  26. Liao J.C., Reiter R.E. Coccidioidomycosis presenting as testicular mass. J Urol. 2001 Oct; 166(4): 1396.
  27. Watabe T., Lin M., Ide H., Donjacour A.A., Cunha G., Witte O.N., Reiter R.E. Growth, regeneration, and tumorigenesis of the prostate activates the PSCA promoter. Proc Natl Acad Sci U S A. 2002 Jan 8; 99(1): 401–6.
  28. DePrimo S.E., Diehn M., Nelson J.B., Reiter R.E., et al. Transcriptional programs activated by exposure of human prostate cancer cells to androgen. Genome Biol. 2002 Jun 14; 3(7): RESEARCH0032.
  29. Jalkut M.W., Reiter R.E. Role of prostate stem cell antigen in prostate cancer research. Curr Opin Urol. 2002 Sep; 12(5): 401–6.
  30. Jain A., Lam A., Vivanco I., Carey M.F., Reiter R.E. Identification of an androgen-dependent enhancer within the PSCA gene. Mol Endocrinol. 2002 Oct; 16(10): 2323–37.
  31. Tran C.P., Lin C., Yamashiro J., Reiter R.E. Prostate stem cell antigen is a marker of late intermediate prostate epithelial cells. Mol Cancer Res. 2002 Dec; 1(2): 113–21.
  32. Palapattu G.S., Reiter R.E. Monoclonal antibody therapy for genitourinary oncology: promise for the future. J Urol. 2002 Dec; 168(6): 2615–23. (Featured Article)
  33. Christiansen J.J., Rajasekaran S.A., Moy P., Butch A., Goodglick L., Gu Z., Reiter R.E., Bander N.H., Rajasekaran A.K. Polarity of prostate-specific membrane antigen, prostate stem cell antigen, and PSA in prostate tissue and cultured epithelial cells. Prostate. 2003 Apr 1; 55(1): 9–19.
  34. Freedland S.J., deGregorio F., Sacoolidge J.C., Elshimali Y.I., Csathy G.S., Dorey F., Reiter R.E., Aronson W.J. Preoperative p27 status predicts PSA failure following radical prostatectomy. J Urol. 2003 Apr; 169(4): 1325–30.
  35. Freedland S.J., deGregorio F., Sacoolidge J.C., Elshimali Y.I., Csathy G.S., Elashoff D.A., Reiter R.E., Aronson W.J. Predicting biochemical recurrence for organ-confined disease using p27 expression. Urology. 2003 Jun; 61(6): 1187–92.
  36. Cheng L., Reiter R.E., Jin Y., Sharon H., Weider J., Lane T.F., Rao J. Immunocytochemical analysis of PSCA as an adjunct marker for detection of urothelial carcinoma in urine specimens. J Urol. 2003 Jun; 169(6): 2094–100.
  37. Han K.R., Seligson D.B., Liu X., Horvath S., Shintaku P.I., Thomas G.V., Said J.W., Reiter R.E. PSCA expression correlates with Gleason score, seminal vesicle invasion, and capsular invasion in prostate cancer. J Urol. 2004 Mar; 171(3): 1117–21.
  38. Chin J.L., Reiter R.E. Genetic alterations in prostate cancer. Curr Urol Rep. 2004 Jun; 5(3): 157–65.
  39. Garraway I.P., Seligson D., Said J., Horvath S., Reiter R.E. Trefoil factor 3 is overexpressed in prostate cancer. Prostate.2004 Nov 1; 61(3): 209–14.
  40. Chin J.L., Reiter R.E. Molecular markers and prostate cancer prognosis. Clin Prostate Cancer. 2004 Dec; 3(3): 157–64.
  41. Thomas G.V., Horvath S., Smith B.L., Crosby K., Schrage M., Said J., deKernion J.B., Reiter R.E., Sawyers C.L. Antibody-based profiling of the PI3K pathway in clinical prostate cancer. Clin Cancer Res. 2004 Dec 15; 10(24): 8351–6.
  42. Gu Z., Rubin M.A., Yang Y., DePrimo S.E., Zhao H., Horvath S., Brooks J.D., Loda M., Reiter R.E. Reg IV: a promising marker of hormone-refractory metastatic prostate cancer. Clin Cancer Res. 2005 Mar 15; 11(6): 2237–43.
  43. Lam J.S., Yamashiro J., Shintaku I.P., Vessella R.L., Jenkins R.B., Horvath S., Said J.W., Reiter R.E. Prostate stem cell antigen is overexpressed in prostate cancer metastases. Clin Cancer Res. 2005 Apr 1; 11(7): 2591–6.
  44. Wente M.N., Jain A., Kono E., Berberat P.O., Giese T., Reber H.A., Friess H., Büchler M.W., Reiter R.E., Hines O.J. Prostate stem cell antigen is a putative immunotherapy target in pancreatic cancer. Pancreas. 2005 Aug; 31(2): 119–25.
  45. Gu Z., Yamashiro J., Kono E., Reiter R.E. Anti-PSCA monoclonal antibody 1G8 induces cell death in vitro and inhibits tumor growth in vivo via an Fc-independent mechanism. Cancer Res. 2005 Oct 15; 65(20): 9495–500.
  46. Reiter R.E., Shurtleff B. What are the operating characteristics of PSA screening for prostate cancer? Nat Clin Pract Urol.2006 Feb; 3(2): 74–5.
  47. Lam J.S., Reiter R.E. Stem cells in prostate and prostate cancer development. Urol Oncol. 2006 Mar–Apr; 24(2): 131–40.
  48. Zemskova M., Wechter W., Baskkirova S., Chen C.S., Reiter R.E., Lilly M.B. Gene expression profiling in R-flurbiprofen–treated prostate cancer: R-flurbiprofen regulates PSCA through AKT activation. Biochem Pharmacol. 2006 Nov 15; 72(10): 1257–67.
  49. Rao D., Gui D., Koski M.E., Wang H., Popoviciu L.M., Reiter R.E., Said J.W. An inverse relation between COX-2 and E-cadherin expression correlates with aggressive histologic features in prostate cancer. Appl Immunohistochem Mol Morphol. 2006 Dec; 14(4): 375–83.
  50. Lin K., Lee S.P., Cho J.S., Reiter R.E., deMarco J.J., Solberg T.D. Improvements in prostate brachytherapy dosimetry due to seed stranding. Brachytherapy. 2007 Jan–Mar; 6(1): 44–8.
  51. Olafsen T, Gu Z, Sherman MA, Leyton JV, Witkosky ME, Shively JE, Raubitschek AA, Morrison SL, Wu AM, Reiter RE. Targeting, imaging, and therapy using a humanized anti-prostate stem cell antigen (PSCA) antibody. J Immunother.2007 May–Jun; 30(4): 396-405.
  52. Litwin MS, Gore JL, Kwan L, Brandeis JM, Lee SP, Withers HR, Reiter RE. Quality of life after surgery, external-beam irradiation, or brachytherapy for early-stage prostate cancer. Cancer. 2007 Jun 1; 109(11): 2239-47.
  53. Reiter RE. Controversies in urologic oncology. Urol Oncol. 2007 Nov–Dec; 25(6): 489.
  54. Pariente N, Morizono K, Virk MS, Petrigliano FA, Reiter RE, Lieberman JR, Chen IS. A novel dual-targeted lentiviral vector leads to specific transduction of prostate-cancer bone metastasis in vivo after systemic administration. Mol Ther.2007 Nov; 15(11): 1973-81.
  55. Reiter RE, Riggs S. What factors affect the PSA relapse-free survival times in patients treated with permanent-seed brachytherapy? Nat Clin Pract Urol. 2007 Dec; 4(12): 650-1.
  56. Gulati M, Raman S, Naini B, Thomas A, Lu D, Reiter RE. Utility of MRI/MRSI in planning robotically assisted laparoscopic radical prostatectomy: histopathologic correlation. Urology. 2008.
  57. Moore ML, Teitell MA, Kim Y, Watabe T, Reiter RE, Witte ON, Dubey P. Deletion of PSCA increases metastasis of TRAMP-induced prostate tumors without altering primary tumor formation. Prostate. 2008 Feb 1; 68(2): 139-51.
  58. Hara T, Miyazaki H, Tran C, Reiter RE. Androgen receptor mediates invasiveness of prostate-cancer cells. Cancer Res.2008 Feb 15; 68(4): 1128-35. van de Poll-Franse LV, Kwan L, Reiter RE, Lee SP, Litwin MS. Cardiovascular disease and health-related quality of life in men with prostate cancer: a 4-year follow-up study. J Urol. 2008 Apr; 179(4): 1362-7.
  59. Wallerand H, Reiter RE, Ravaud A. Molecular targeting in advanced/metastatic bladder cancer according to signaling pathways. Curr Opin Urol. 2008 Sep; 18(5): 524-32.
  60. Leyton JV, Olafsen T, Lepin EJ, Hahm S, Bauer KB, Reiter RE, Wu AM. Humanized radioiodinated minibody for imaging PSCA-expressing tumors. Clin Cancer Res. 2008 Nov 15; 14(22): 7488-96.
  61. Reiter RE. The urologist’s role in basic and translational research: personal reflections. Urol Oncol. 2009 Mar–Apr; 27(2): 127-8.
  62. Leyton JV, Olafsen T, Sherman MA, Bauer KB, Aghajanian P, Reiter RE, Wu AM. Engineered humanized diabodies for microPET imaging of PSCA-expressing tumors. Protein Eng Des Sel. 2009 Mar; 22(3): 209-16.
  63. Li Y, Wang L, Zhang M, Melamed J, Liu X, Reiter RE, et al. LEF1 in androgen-independent prostate cancer: regulation of androgen receptor expression, growth, and invasion. Cancer Res. 2009 Apr 15; 69(8): 3332-8.
  64. Fondrevelle ME, Kantelip B, Reiter RE, Chopin DK, Thiery JP, Monnien F, Bittard H, Wallerand H. Twist expression impacts survival in human bladder cancer and is influenced by smoking status. Urol Oncol. 2009 May–Jun; 27(3): 268-76.
  65. Gore JL, Kwan L, Lee SP, Reiter RE, Litwin MS. Survivorship beyond convalescence: 48-month QoL outcomes after treatment for localized prostate cancer. J Natl Cancer Inst. 2009 Jun 16; 101(12): 888-92.
  66. Wallerand H, Cai Y, Wainberg ZA, Garraway I, Lascombe I, Nicolle G, Thiery JP, Bittard H, Radvanyi F, Reiter RE. Phospho-Akt pathway activation and inhibition depend on N-cadherin or phospho-EGFR in invasive bladder-cancer lines. Urol Oncol. 2010 Mar–Apr; 28(2): 180-8.
  67. Garraway IP, Sun W, Tran CP, Perner S, Zhang B, Goldstein AS, Hahm SA, Haider M, Head CS, Reiter RE, Rubin MA, Witte ON. Human prostate sphere-forming cells represent basal epithelial cells capable of glandular regeneration in vivo. Prostate. 2010 Apr 1; 70(5): 491-501.
  68. Lepin EJ, Leyton JV, Zhou Y, Olafsen T, Salazar FB, McCabe KE, Hahm S, Marks JD, Reiter RE, Wu AM. An affinity-matured minibody for PET imaging of PSCA-expressing tumors. Eur J Nucl Med Mol Imaging. 2010 Aug; 37(8): 1529-38.
  69. Wallerand H, Robert G, Pasticier G, Ravaud A, Ballanger P, Reiter RE, Ferrière J-M. TWIST as a target in advanced bladder and prostate cancer. Urol Oncol. 2010 Sep–Oct; 28(5): 473-9.
  70. Tanaka H, Kono E, Tran CP, Miyazaki H, Yamashiro J, Shimomura T, Fazil L, Wada R, Huang J, Vessella R.L., An J, Horvath S, Gleave M, Rettig M.B., Wainberg Z.A., Reiter R.E.
  71. Monoclonal antibody targeting of N-cadherin inhibits prostate-cancer growth, metastasis, and castration resistance. Nat Med. 2010 Dec; 16(12): 1414-20.
  72. Wallerand H, Bernhard J-C, Culine S, Ballanger P, Robert G, Reiter R.E., Ferrière J-M, Ravaud A. Targeted therapies in non-muscle-invasive bladder cancer. Urol Oncol. 2011 Jan–Feb; 29(1): 4-11.
  73. Goldstein A.S., Drake J.M., Burnes D.L., Finley D.S., Zhang H., Reiter R.E., Huang J., Witte O.N. Purification and transformation of epithelial progenitor cells from primary human prostate. Nat Protoc. 2011 May; 6(5): 656-67.
  74. Tan N, Margolis D.J., McClure T.D., Thomas A., Finley D.S., Reiter R.E., Huang J., Raman S.S. Radical prostatectomy: value of prostate MRI in surgical planning. Abdom Imaging. 2011 Oct 13.
  75. Nagarajan R, Margolis D., Raman S., Sheng K., King C., Reiter R.E., Thomas M.A. Correlation of Gleason scores with diffusion-weighted MRI findings. Adv Urol. 2012; 2012: 374805. Epub 2011 Dec 15.
  76. McClure T.D., Margolis D.J., Reiter R.E., Sayre J.W., Thomas M.A., Nagarajan R., Gulati M., Raman S.S. MR imaging to determine neurovascular bundle preservation at robotic prostatectomy. Radiology. 2012 Jan 24.
  77. Finley D.S., Margolis D., Raman S.S., Ellingson B.M., Natarajan S., Tan N., Huang J., Reiter R.E. Fine-tuning robot-assisted radical prostatectomy planning with MRI. Urol Oncol. 2011 Sep 7.
  78. Finley D.S., Ellingson B.M., Natarajan S., Zaw T.M., Raman S.S., Schulam P.S., Reiter R.E., Margolis D. Diffusion tensor MR tractography of the prostate: feasibility for mapping periprostatic fibers. Urology. 2012 Jul; 80(1): 219-23.
  79. Nagarajan R., Margolis D., Raman S., Sarma M.K., Sheng K., King C.R., Verma G., Sayre J., Reiter R.E., Thomas M.A. MR spectroscopic and diffusion-weighted imaging of prostate cancer with Gleason scores. J Magn Reson Imaging. 2012 Sep; 36(3): 697-703.
  80. Thomas M.A., Nagarajan R., Huda A., Margolis D., Sarma M.K., Sheng K., Reiter R.E., Raman S.S. Multidimensional MR spectroscopic imaging of prostate cancer in vivo. NMR Biomed. 2013. PMID: 23904127.
  81. Seiler D, Zheng J, Liu G, Wang S, Yamashiro J, Reiter RE, Huang J, Zeng G. Enrichment of putative prostate cancer stem cells after androgen deprivation: upregulation of pluripotency transactivators concurs with resistance in LNCaP cell lines. Prostate. 2013. PMID: 23728788.
  82. Sonn G.A., Chang E., Natarajan S., Margolis D.J., Macariran M., Lieu P., Huang J., Dorey F.J., Reiter R.E., Marks L.S. Value of targeted prostate biopsy using magnetic resonance–ultrasound fusion in men with prior negative biopsy and elevated PSA. Eur Urol. 2013. PMID: 23523537.
  83. Chamie K., Sonn G.A., Finley D.S., Tan N., Margolis D.A., Raman S.S., Natarajan S., Huang J., Reiter R.E. The role of MRI in delineating clinically significant disease. Urology. 2014. PMID: 24468511.
  84. Knowles S.M., Zettlitz K.A., Tavare R., Rochefort M.M., Salazar F.B., Stout D.B., Yazaki P.J., Reiter R.E., Wu A.M. Quantitative ImmunoPET of prostate cancer xenografts with ⁸⁹Zr- and ¹²⁴I-labeled anti-PSCA A11 minibody. J Nucl Med.2014; 55(3): 452-9.
  85. White N.S., McDonald C.R., Farid N., Kuperman J., Karow D., Schenker-Ahmed N.M., et al. Diffusion-weighted imaging in cancer: physical foundations and applications of restriction spectrum imaging. Cancer Res. 2014 Sep. PMID: 25183788.
  86. Sonn G.A., Filson C.P., Chang E., Natarajan S., Margolis D.J., Lieu P., Huang J., Dorey F.J., Reiter R.E., Marks L.S. Electronic tracking of specific tumor sites in men undergoing active surveillance of prostate cancer: initial experience. Urol Oncol. 2014 Oct. PMID: 25027689.
  87. Le J.D., Stephenson S., Brugger M., Lu D.Y., Lieu P., Sonn G.A., Natarajan S., Dorey F.J., Huang J., Margolis D.J., Reiter R.E., Marks L.S. MRI/ultrasound fusion biopsy for prediction of final pathology. J Urol. 2014 Nov. PMID: 24793118.
  88. Knowles S.M., Zettlitz K.A., Reiter R.E., Wu A.M. ImmunoPET using ¹²⁴I-anti-PSCA A11 minibody for imaging disease progression and therapy response in mouse xenografts. Clin Cancer Res. 2014 Dec 15; 20(24): 6367-78. PMID: 25326233.
  89. Le J., Tan N., Huang J., Margolis D.J., Raman S., Marks L.S., Reiter R.E. Multifocality and prostate cancer detection by multiparametric MRI: correlation with whole-mount histopathology. Eur Urol. 2015 Mar; 67(3): 569-76. PMID: 25257029.
  90. Liss M.A., White N.S., Parsons J.K., Schenker-Ahmed N.M., Rakow-Penner R., Kuperman J.M., et al. MRI-derived restriction spectrum imaging cellularity index is associated with high-grade prostate cancer on radical prostatectomy. Front Oncol. 2015 Feb 17; 5:30. PMID: 25741473.
  91. Rakow-Penner R.A., White N.S., Parsons J.K., et al. MRI restriction spectrum imaging for prostate cancer: proof of principle and initial clinical experience. Prostate Cancer Prostatic Dis. 2015 Mar; 18(1): 81-5. PMID: 25559097.
  92. Kang J.J., Reiter R.E., Steinberg M.L., King C.R. Ultrasensitive PSA after prostatectomy identifies patients requiring postoperative radiotherapy. J Urol. 2015 May; 193(5): 1532-8. PMID: 25463990.
  93. Behesnilian A.S., Reiter R.E. Risk stratification of prostate cancer in the modern era. Curr Opin Urol. 2015 May; 25(3): 246-51. PMID: 25730325.
  94. Tan N., Le J., Huang J., Margolis D.J., Raman S.S., Reiter R.E. Detected and missed prostate cancer foci on 3 T endorectal coil multiparametric MRI correlated with whole-mount histopathology. Am J Roentgenol. 2015.
  95. Sonn G.A., Behesnilian A., Zhang Z., Lepin E.J., Bentolila L.A., Lawrence D.J.P., Zettlitz K.A., Wu A.M., Reiter R.E. Fluorescent image-guided surgery with an anti-PSCA diabody enables targeted resection of prostate cancer xenografts in real time. Clin Cancer Res. 2016 Oct.
  96. Kang J.J., Reiter R.E., Steinberg M.L., King C.R. Wrong to be right: effects of laterality on margin status and biochemical recurrence following radical prostatectomy. Am J Clin Oncol. 2015 Jul 31 [Epub ahead of print].
  97. Rakow-Penner R.A., White N.S., Margolis D.J., et al. Prostate diffusion imaging with distortion correction. Magn Reson Imaging. 2015 Nov; 33(9): 1178-81. PMID: 26220859.
  98. Filson C.P., Natarajan S., Margolis D.J., Huang J., Lieu P., Dorey F.J., Reiter R.E., Marks L.S. Prostate cancer detection with MR-ultrasound fusion biopsy: role of systematic and targeted biopsies. Cancer. 2016 Jan 7. PMID: 26749141.
  99. Priester A., Natarajan S., Khoshnoodi P., Margolis D.J., Raman S.S., Reiter R.E., Huang J., Grundfest W., Marks L.S. MRI underestimation of prostate cancer geometry: use of patient-specific molds to correlate images with whole-mount pathology. J Urol. 2016 Jul 30. PMID: 27484386.
  100. Stoyanova T., Riedinger M., Lin S., et al. Activation of Notch1 synergizes with multiple pathways in promoting castration-resistant prostate cancer. Proc Natl Acad Sci U S A. 2016 Oct 18; 113(42): E6457-E6466. PMID: 27694579.
  101. Reiter R.E. Risk stratification of prostate cancer 2016. Scand J Clin Lab Invest Suppl. 2016; 245:S54-9. PMID: 27533326.
  102. Pandit-Taskar N., O’Donoghue J.A., Ruan S., et al. First-in-human imaging with ⁸⁹Zr-Df-IAB2M anti-PSMA minibody in metastatic prostate cancer. J Nucl Med. 2016 Dec; 57(12): 1858-64. PMID: 27516450.
  103. Kishan A.U., Shaikh T., Wang P.C., Reiter R.E., et al. Clinical outcomes for Gleason score 9–10 prostate adenocarcinoma treated with radiotherapy or radical prostatectomy: a multi-institutional analysis. Eur Urol. 2016. PMID: 27452951.
  104. Prado K., Reiter R.E. Is targeted biopsy applicable to patients on active surveillance? Eur Urol. 2016 Jun 9. PMID: 27292867.
  105. Taneja S.S., Bennett J., Coleman J., et al. Phase I/II trial of WST11 vascular-targeted photodynamic therapy for hemi-ablation of unilateral low-risk prostate cancer in U.S. men. J Urol. 2016 Oct; 196(4): 1096-104. PMID: 27291652.
  106. Priester A., Natarajan S., Khoshnoodi P., et al. MRI underestimation of prostate cancer geometry using patient-specific molds and whole-mount pathology. J Urol. 2017 Feb; 197(2): 320-6.
  107. Hegde J.V., Margolis D.J., Wang P.C., Reiter R.E., Huang J., Steinberg M.L., Kamrava M. Distribution of satellite lesions in intermediate-/high-risk prostate cancer: implications for focused radiotherapy. Prostate Cancer Prostatic Dis. 2017 Jun; 20(2): 241-8.
  108. Jamshidi N., Margolis D.J., Raman S., Huang J., Reiter R.E., Kuo M.D. Multiregional radiogenomic assessment of prostate microenvironments with multiparametric MRI and whole-exome sequencing. Radiology. 2017 Jul; 284(1): 109-19.
  109. Hegde J.V., Veruttipong D., Said J.W., Reiter R.E., Steinberg M.L., King C.R., Kishan A.U. Prostate Cancer Antigen 3 score does not predict adverse pathology or progression-free survival. Urology. 2017 Sep; 107: 171-7.
  110. Miller E.T., Salmasi A., Reiter R.E. Anatomic and molecular imaging in prostate cancer. Cold Spring Harb Perspect Med.2017 Jul 14; a030619.
  111. Johnson D.C., Reiter R.E. Multiparametric magnetic resonance imaging as a management decision tool. Transl Androl Urol. 2017 Jun; 6(3): 472-82.
  112. Nassiri N., Chang E., Lieu P., Priester A.M., Margolis D.J.A., Huang J., Reiter R.E., Dorey F.J., Marks L.S., Natarajan S. Focal therapy eligibility determined by MRI/ultrasound fusion biopsy. J Urol. 2017.
  113. Eiber M., Herrmann K., Calais J., Hadaschik B., Giesel F.L., Hartenbach M., Hope T.A., Reiter R., et al. Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed miR NM classification for PSMA-ligand PET/CT. J Nucl Med. 2017 Nov 9.
  114. Donin N.M., Reiter R. Why targeting PSMA is a game changer in the management of prostate cancer – a urologist’s perspective. J Nucl Med. 2017 Oct 6.
  115. Wyatt A.W., Annala M., Aggarwal R., et al. Concordance of circulating tumor DNA and matched metastatic tissue biopsy in prostate cancer. J Natl Cancer Inst. 2017 Dec 1; 109(12). PMID: 28986509.
  116. Priceman S.J., Gerdts E.A., Tilakawardane D., et al. Co-stimulatory signaling determines antigen sensitivity and persistence of CAR T cells targeting PSCA⁺ metastatic prostate cancer. Oncoimmunology. 2017 Oct 16; 7(2): e1380764.
  117. Tan N., Shen L., Khoshnoodi P., et al. Pathological and 3 T volumetric MR predictors of biochemical recurrence after robotic radical prostatectomy: correlation with whole-mount histopathology. J Urol. 2017.
  118. Calais J., Fendler W.P., Eiber M., et al. Impact of ⁶⁸Ga-PSMA-11 PET/CT on management of prostate cancer with biochemical recurrence. J Nucl Med. 2017 Dec 14.
  119. Crawford E.D., Koo P.J., Shore N., et al.; (Prostate Cancer RADAR III Group). A clinician’s guide to next-generation imaging in advanced prostate cancer. J Urol. 2018 Aug 2.
  120. Wu H.H., Priester A., Khoshnoodi P., Zhang Z., Shakeri S., Afshari Mirak S., Asvadi N.H., Ahuja P., Sung K., Natarajan S., Sisk A., Reiter R.E., Raman S., Enzmann D. A system using patient-specific 3D-printed molds to spatially align in vivo MRI with ex vivo MRI and whole-mount histopathology for prostate cancer research. J Magn Reson Imaging. 2018 Aug 2. doi: 10.1002/jmri.26189.
  121. Salmasi A., Faiena I., Wu J., Sisk A.E. Jr., Sachveda A., Vandel J.J., Chamie K., Marks L.S., Reiter R.E. Radical prostatectomy then and now: surgical overtreatment of prostate cancer is declining from 2009 to 2016 at a tertiary referral center. Urol Oncol. 2018 Jul 28.
  122. Quigley D.A., Dang H.X., Zhao S.G., et al. Genomic hallmarks and structural variation in metastatic prostate cancer. Cell.2018 Jul 26; 174(3): 758–769.
  123. Sandler K.A., Cook R.R., Ciezki J.P., et al. Clinical outcomes for patients with Gleason score 10 prostate adenocarcinoma: results from a multi-institutional consortium study. Int J Radiat Oncol Biol Phys. 2018 Jul 15; 101(4): 883–888.
  124. Asvadi N.H., Afshari Mirak S., Mohammadian Bajgiran A., et al. 3T multiparametric MRI (PIRADS v2) for index prostate cancer lesion detection in transition and peripheral zones with whole-mount histopathology correlation. Abdom Radiol (NY). 2018 May 3.
  125. Calais J., Kishan A.U., Cao M., et al. Potential impact of ⁶⁸Ga-PSMA-11 PET/CT on prostate cancer definitive radiation therapy planning. J Nucl Med. 2018 Apr 13.
  126. Zettlitz K.A., Tsai W.K., Knowles S.M., Kobayashi N., Donahue T.R., Reiter R.E., Wu A.M. Dual-modality immunoPET and near-infrared fluorescence imaging of pancreatic cancer using an anti-PSCA cys-diabody. J Nucl Med. 2018 Mar 30.
  127. Lückerath K., Stuparu A.D., Wei L., Kim W., Radu C.G., Mona C.E., Calais J., Rettig M.B., Reiter R.E., Czernin J., Slavik R., Herrmann K., Eiber M., Fendler W.P. Detection threshold and reproducibility of ⁶⁸Ga-PSMA-11 PET/CT in a mouse model of prostate cancer. J Nucl Med. 2018 Mar 30.
  128. Salmasi A., Said J., Shindel A.W., et al. 17-Gene Genomic Prostate Score assay provides independent information on adverse pathology in the setting of combined mpMRI fusion-targeted and systematic biopsy. J Urol. 2018 Mar 7. (Cover Article).
  129. Kishan A.U., Cook R.R., Ciezki J.P., et al. Radical prostatectomy, external beam radiotherapy, or EBRT with brachytherapy boost and disease progression in Gleason 9-10 prostate cancer. JAMA. 2018 Mar 6; 319(9): 896-905.
  130. Faiena I., Salmasi A., Mendhiratta N., et al. PI-RADS v2 category on 3 T mpMRI predicts oncologic outcomes in Gleason 3+4 prostate cancer on biopsy. J Urol. 2018 Aug 21. (Cover Story).
  131. Crawford E.D., Koo P.J., Shore N., et al. A clinician’s guide to next-generation imaging in advanced prostate cancer (RADAR III Group). J Urol. 2018 Aug 2. PMID: 30077557.
    Priester A.M., Wu H., Khoshnoodi P., et al. Registration accuracy of patient-specific 3D prostate molds for correlating pathology with MRI. IEEE Trans Biomed Eng. 2018 Apr 19. PMID: 29993431.
  132. Tsai W.K., Zettlitz K.A., Tavaré R., Kobayashi N., Reiter R.E., Wu A.M. Dual-modality immunoPET/fluorescence imaging of prostate cancer with an anti-PSCA cys-minibody. Theranostics. 2018 Nov.
  133. Zhang M., Zettlitz K.A., Kobayashi N., Wu A.M., Reiter R.E. Near-infrared-dye labeled anti-PSCA A11 minibody enables intraoperative fluorescence imaging and targeted surgery in translational models of prostate cancer. Clin Cancer Res. 2019.
  134. Sadun T.Y., Reiter R.E. Adjusting our approach for mpMRI-based targeted prostate biopsies: considerations after the FUTURE trial. Eur Urol. 2018 Dec 24.
  135. Johnson D.C., Raman S.S., Mirak S.A., et al. Detection of individual prostate cancer foci via multiparametric MRI (Cover Article May 2019 Edition). Eur Urol. 2018 Nov 30.
  136. Lückerath K., Wei L., Fendler W.P., et al. Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer. EJNMMI Res. 2018.
  137. Kishan A.U., Wang X., Seiferheld W., et al. Association of Gleason grade with ADT duration and survival outcomes: systematic review and patient-level meta-analysis. JAMA Oncol. 2018 Sep 20.
  138. Afshari Mirak S., Shakeri S., Mohammadian Bajgiran A., et al. 3 T mpMRI with and without endorectal coil for prostate cancer detection and staging: whole-mount histopathology correlation in 429 patients. J Urol. 2018 Sep 28.
  139. Polverari G., Ceci F., Allen-Auerbach M., et al. Solitary mucinous prostate adenocarcinoma lung metastasis detected by ⁶⁸Ga-PSMA-11 PET/CT. Clin Genitourin Cancer. 2018 Sep 7.
  140. Houlahan K.E., Salmasi A., Sadun T.Y., et al. Molecular hallmarks of mpMRI visibility in prostate cancer. Eur Urol. 2019 Jul; 76(1): 18–23. PMID: 30685078.
  141. Simopoulos D.N., Sisk A.E. Jr., Priester A., et al. Cancer core length from targeted biopsy as an index of tumor volume and stage. BJU Int. 2019 Aug; 124(2): 275–281.
  142. Lubin D.J., Holden S.B., Rettig M.B., Reiter R.E., King C.R., Lee J.M., Wallace D.W., Calais J. Prostate cancer pulmonary metastasis presenting as ground-glass nodule on ⁶⁸Ga-PSMA-11 PET/CT. Clin Nucl Med. 2019 May; 44(5): e353-e356.
  143. Nickols N.G., Nazarian R., Zhao S.G., et al. MEK-ERK signaling is a therapeutic target in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2019 Feb 25.
  144. Aggarwal R.R., Quigley D.A., Huang J., et al. Whole-genome and transcriptional analysis of treatment-emergent small-cell neuroendocrine prostate cancer demonstrates intraclass heterogeneity. Mol Cancer Res. 2019 Jun; 17(6): 1235-1240.
  145. Fendler W.P., Calais J., Eiber M., et al. Assessment of ⁶⁸Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective trial. JAMA Oncol. 2019 Jun 1; 5(6): 856-863.
  146. Chen W.S., Aggarwal R., Zhang L., et al. Genomic drivers of poor prognosis and enzalutamide resistance in mCRPC. Eur Urol. 2019 Mar 27.
  147. Parikh N.R., Huiza C., Patel J.S., et al. Systemic and tumor-directed therapy for oligometastatic prostate cancer: phase II trial protocol. BMC Cancer. 2019 Apr 1; 19(1): 291.
  148. Sandler K.A., Cook R.R., Ciezki J.P., et al. Prostate-only vs whole-pelvis radiation ± brachytherapy boost for Gleason grade group 5 disease: retrospective analysis. Eur Urol. 2019 Apr 13. PMID: 30992160.
  149. Wibulpolprasert P., Raman S.S., Hsu W., et al. Detection and localization of prostate cancer at 3 T mpMRI using PI-RADS segmentation. AJR Am J Roentgenol. 2019 Apr 17.
  150. Kang J.J., Reiter R.E., Steinberg M.L., King C.R. First post-prostatectomy ultrasensitive PSA predicts survival in high-risk patients. Eur Urol Oncol. 2018 Oct; 1(5): 378-385.
  151. Dorff T.B., Fanti S., Farolfi A., Reiter R.E., Sadun T.Y., Sartor O. The evolving role of PSMA-based diagnostics and therapeutics in prostate cancer. Am Soc Clin Oncol Educ Book. 2019; 39: 321-330.
  152. Johnson D.C., Yang J.J., Kwan L., et al. Do contemporary imaging and biopsy techniques reliably identify unilateral prostate cancer? Implications for hemi-ablation selection. Cancer. 2019 Sep 1; 125(17): 2955-2964.
  153. Johnson D.C., Reiter R.E. Focal therapy should not be considered for men with Gleason grade 3–5 prostate cancer. Eur Urol Focus. 2019 Jun 12.
  154. Zettlitz K.A., Tsai W.K., Knowles S.M., et al. [⁸⁹Zr]A2cDb immuno-PET of prostate cancer in human PSCA knock-in syngeneic model. Mol Imaging Biol. 2019 Jun 17.
  155. Bajgiran A.M., Mirak S.A., Sung K., et al. Apparent diffusion coefficient ratio vs conventional ADC for detecting clinically significant prostate cancer with 3 T MRI. AJR Am J Roentgenol. 2019 Jun 19.
  156. Calais J., Ceci F., Eiber M., et al. Fluciclovine PET-CT and ⁶⁸Ga-PSMA-11 PET-CT in early biochemical recurrence after prostatectomy: comparative trial. Lancet Oncol. 2019 Jul 30.
  157. Wang C., Raldow A.C., Nickols N.G., et al. Underutilization of androgen deprivation therapy with EBRT in high-grade prostate cancer. Eur Urol Oncol. 2019 Feb 1.
  158. Osadchiy V., Eleswarapu S.V., Mills S.A., Pollard M.E., Reiter R.E., Mills J.N. Efficacy of pre-prostatectomy multimodal penile rehabilitation on recovery of erectile function. Int J Impot Res. 2020 May; 32(3): 323-328.
  159. Gillessen S., Attard G., Beer T.M., et al.; Advanced Prostate Cancer Consensus Conference (2020). Management of patients with advanced prostate cancer: report of the APCCC 2019. Eur Urol. 2020 Apr; 77(4): 508-547.
  160. Fendler WP, Ferdinandus J, Czernin J, Eiber M, Flavell RR, Behr SC, Wu IK, Lawhn-Heath C, Pampaloni MH, Reiter RE, Rettig MB, Gartmann J, Murthy V, Slavik R, Carroll PR, Herrmann K, Calais J, Hope TA. Impact of 68Ga-PSMA-11 PET on the Management of Recurrent Prostate Cancer in a Prospective Single-Arm Clinical Trial. J Nucl Med. 2020 May 1.
  161. Alumkal JJ, Sun D, Lu E, Beer TM, Thomas GV, Latour E, Aggarwal R, Cetnar J, Ryan CJ, Tabatabaei S, Bailey S, Turina CB, Quigley DA, Guan X, Foye A, Youngren JF, Urrutia J, Huang J, Weinstein AS, Friedl V, Rettig M, Reiter RE, Spratt DE, Gleave M, Evans CP, Stuart JM, Chen Y, Feng FY, Small EJ, Witte ON, Xia Z. Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance. Proc Natl Acad Sci U S A. 2020 Jun 2;117(22):12315-12323.
  162. Kishan AU, Romero T, Alshalalfa M, Liu Y, Tran PT, Nickols NG, Ye H, Sajed D, Rettig MB, Reiter RE, Garraway IP, Spratt DE, Freedland SJ, Zhao X, Li Z, Deek M, Livingstone J, Mahal BA, Nguyen PL, Feng FY, Den RB, Schaeffer EM, Lotan TL, Karnes RJ, Klein EA, Ross AE, Grogan T, Davicioni E, Elashoff D, Boutros PC, Weidhaas JB. Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate Cancer. Eur Urol. 2020 May 24:S0302-2838.
  163. Parikh NR, Chang EM, Nickols NG, Rettig MB, Raldow AC, Steinberg ML, Koontz BF, Vapiwala N, Deville C, Feng FY, Spratt DE, Reiter RE, Phillips R, Ost P, Tran PT, Kishan AU. Cost-effectiveness of metastasis-directed therapy in oligorecurrent hormone-sensitive prostate cancer. Int J Radiat Oncol Biol Phys. 2020 Jun 13:S0360-3016.
  164. Parikh NR, Kishan AU, Kane N, Diaz-Perez S, Ganapathy E, Nazarian R, Felix C, Mathis C, Bradley M, Sachdeva A, Wyatt B, Basehart V, Zomorodian N, Lin L, King CR, Kupelian PA, Rettig MB, Steinberg ML, Cao M, Knudsen BS, Elashoff D, Schaue D, Reiter RE, Nickols NG. Phase I Trial of Stereotactic Body Radiotherapy Neoadjuvant to Radical Prostatectomy for Patients with High-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2020 Jun 17:S0360-3016(20)31251-7.
  165. Nickols NG, Ganapathy E, Nguyen C, Kane N, Lin L, Diaz-Perez S, Nazarian R, Mathis C, Felix C, Basehart V, Zomorodian N, Kwak J, Kishan AU, King CR, Kupelian PA, Rettig MB, Steinberg ML, Cao M, Knudsen BS, Chu FI, Romero T, Elashoff D, Reiter RE, Schaue D. The intraprostatic immune environment after stereotactic body radiotherapy is dominated by myeloid cells. Prostate Cancer Prostatic Dis. 2020 Jul 9.
  166. Zhao SG, Chen WS, Li H, Foye A, Zhang M, Sjöström M, Aggarwal R, Playdle D, Liao A, Alumkal JJ, Das R, Chou J, Hua JT, Barnard TJ, Bailey AM, Chow ED, Perry MD, Dang HX, Yang R, Moussavi-Baygi R, Zhang L, Alshalalfa M, Laura Chang S, Houlahan KE, Shiah YJ, Beer TM, Thomas G, Chi KN, Gleave M, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Yvonne Kim M, Fong L, Spratt DE, Morgan TM, Bose R, Huang FW, Li H, Chesner L, Shenoy T, Goodarzi H, Asangani IA, Sandhu S, Lang JM, Mahajan NP, Lara PN, Evans CP, Febbo P, Batzoglou S, Knudsen KE, He HH, Huang J, Zwart W, Costello JF, Luo J, Tomlins SA, Wyatt AW, Dehm SM, Ashworth A, Gilbert LA, Boutros PC, Farh K, Chinnaiyan AM, Maher CA, Small EJ, Quigley DA, Feng FY. The DNA methylation landscape of advanced prostate cancer. Nat Genet. 2020 Jul 13.
  167. Tsai WK, Zettlitz KA, Dahlbom M, Reiter RE, Wu AM. Evaluation of [131I]I- and [177Lu]Lu-DTPA-A11 Minibody for Radioimmunotherapy in a Preclinical Model of PSCA-Expressing Prostate Cancer. Mol Imaging Biol. 2020 Jul 13.
  168. Guan X, Sun D, Lu E, Urrutia JA, Reiter RE, Rettig M, Evans CP, Lara P Jr, Gleave M, Beer TM, Thomas GV, Huang J, Aggarwal RR, Quigley DA, Foye A, Chen WS, Youngren J, Weinstein AS, Stuart JM, Feng FY, Small EJ, Xia Z, Alumkal JJ. Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2020 Jul 29.
  169. Lec PM, Lenis AT, Golla V, Brisbane W, Shuch B, Garraway I, Reiter R, Chamie K. The Role of Opioids and Their Receptors in Urologic Malignancy: A Review. J Urol. 2020 Jun 9.
  170. Zhang Z, Wu HH, Priester A, Magyar C, Afshari Mirak S, Shakeri S, Mohammadian Bajgiran A, Hosseiny M, Azadikhah A, Sung K, Reiter RE, Sisk AE, Raman S, Enzmann DR. Prostate Microstructure in Prostate Cancer Using 3-T MRI with Diffusion-Relaxation Correlation Spectrum Imaging: Validation with Whole-Mount Digital Histopathology. Radiology. 2020 Aug;296(2):348-355.
  171. Kishan AU, Reiter RE. Caught Between a Rock and a Hard Place. Int J Radiat Oncol Biol Phys. 2020 Mar 12.
  172. Wibulpolprasert P, Raman SS, Hsu W, Margolis DJA, Asvadi NH, Khoshnoodi P, Moshksar A, Tan N, Ahuja P, Maehara CK, Sisk A, Sayre J, Lu DSK, Reiter RE. Influence of the Location and Zone of Tumor in Prostate Cancer Detection and Localization on 3-T Multiparametric MRI Based on PI-RADS Version 2. AJR Am J Roentgenol. 2020 May;214(5):1101-1111.
  173. Chen WS, Feng EL, Aggarwal R, Foye A, Beer TM, Alumkal JJ, Gleave M, Chi KN, Reiter RE, Rettig MB, Evans CP, Small EJ, Sharifi N, Zhao SG. Germline polymorphisms associated with impaired survival outcomes and somatic tumor alterations in advanced prostate cancer. Prostate Cancer Prostatic Dis. 2020 Jun;23(2):316-323.
  174. Kishan AU, Chu FI, King CR, Seiferheld W, Spratt DE, Tran P, Wang X, Pugh SE, Sandler KA, Bolla M, Maingon P, De Reijke T, Nickols NG, Rettig M, Drakaki A, Liu ST, Reiter RE, Chang AJ, Feng FY, Sajed D, Nguyen PL, Kupelian PA, Steinberg ML, Boutros PC, Elashoff D, Collette L, Sandler HM. Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized Trials. Eur Urol. 2020 Feb;77(2):201-208.
  175. Afshari Mirak S, Mohammadian Bajgiran A, Sung K, Asvadi NH, Markovic D, Felker ER, Lu D, Sisk A, Reiter RE, Raman SS. Dynamic contrast-enhanced MR imaging: the role of qualitative and quantitative parameters for evaluating prostate tumors stratified by Gleason score and PI-RADS v2. Abdom Radiol (NY). 2020 Jul;45(7):2225-2234.
  176. Sonni I, Eiber M, Fendler WP, Alano RM, Vangala SS, Kishan AU, Nickols N, Rettig MB, Reiter RE, Czernin J, Calais J. Impact of 68Ga-PSMA-11 PET/CT on Staging and Management of Prostate Cancer Patients in Various Clinical Settings: A Prospective Single-Center Study. J Nucl Med. 2020 Aug;61(8):1153-1160.
  177. Fendler WP, Calais J, Eiber M, Simko JP, Kurhanewicz J, Santos RD, Feng FY, Reiter RE, Rettig MB, Nickols NG, Kishan AU, Slavik R, Carroll PR, Lawhn-Heath C, Herrmann K, Czernin J, Hope TA. False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial. Eur J Nucl Med Mol Imaging. 2021 Feb;48(2):501-508.
  178. Lenis AT, Pooli A, Lec PM, Sadun TY, Johnson DC, Lebacle C, Fendler WP, Eiber M, Czernin J, Reiter RE, Calais J. Prostate-specific Membrane Antigen PET/CT Compared with Conventional Imaging for Initial Staging of Treatment-Naïve Intermediate- and High-Risk Prostate Cancer. Eur Urol Oncol. 2022 Oct;5(5):544-552.
  179. Chen WS, Haynes WA, Waitz R, Kamath K, Vega-Crespo A, Shrestha R, Zhang M, Foye A, Baselga Carretero I, Perez Garcilazo I, Zhang M, Zhao SG, Sjöström M, Quigley DA, Chou J, Beer TM, Rettig M, Gleave M, Evans CP, Lara P, Chi KN, Reiter RE, Alumkal JJ, Ashworth A, Aggarwal R, Small EJ, Daugherty PS, Ribas A, Oh DY, Shon JC, Feng FY. Autoantibody Landscape in Patients with Advanced Prostate Cancer. Clin Cancer Res. 2020 Dec;26(23):6204-6214.
  180. Pooli A, Johnson DC, Shirk J, Markovic D, Sadun TY, Sisk AE Jr, Mohammadian Bajgiran A, Afshari Mirak S, Felker ER, Hughes AK, Raman SS, Reiter RE. Predicting Pathological Tumor Size in Prostate Cancer Based on Multiparametric Prostate Magnetic Resonance Imaging and Preoperative Findings. J Urol. 2021 Feb;205(2):444–451.
  181. Crawford ED, Andriole G, Freedland SJ, Garnick M, Gomella LG, Henderson J, Higano CT, Kader AK, Kane C, Keane TE, Koo PJ, Petrylak DP, Reiter RE, Slovin SF, Yu EY. Evolving Understanding and Categorization of Prostate Cancer: Preventing Progression to Metastatic Castration-Resistant Prostate Cancer: RADAR IV. Can J Urol. 2020 Oct;27(5):10352–10362.
  182. Lin L, Kane N, Kobayashi N, Kono EA, Yamashiro JM, Nickols NG, Reiter RE. High-Dose per Fraction Radiotherapy Induces Both Antitumor Immunity and Immunosuppressive Responses in Prostate Tumors. Clin Cancer Res. 2021 Mar;27(5):1505–1515.
  183. Valle LF, Lehrer EJ, Markovic D, Elashoff D, Levin-Epstein R, Karnes RJ, Reiter RE, Rettig M, Calais J, Nickols NG, Dess RT, Spratt DE, Steinberg ML, Nguyen PL, Davis BJ, Zaorsky NG, Kishan AU. A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER). Eur Urol. 2021 Sep;80(3):280–292.
  184. Murthy V, Sonni I, Jariwala N, Juarez R, Reiter RE, Raman SS, Hope TA. The Role of PSMA PET/CT and PET/MRI in the Initial Staging of Prostate Cancer. Eur Urol Focus. 2021 Mar;7(2):258–266.
  185. Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, Gillessen S, Van der Kwast T, Bristow RG. Prostate Cancer. Nat Rev Dis Primers. 2021 Feb 4;7(1):9.
  186. Schaeffer E, Srinivas S, Antonarakis ES, Armstrong AJ, Bekelman JE, Cheng H, D’Amico AV, Davis BJ, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Horwitz EM, Ippolito JE, Kuettel MR, Lang JM, McKay R, McKenney J, Netto G, Penson DF, Pow-Sang JM, Reiter R, Richey S, Roach III M, Rosenfeld S, Shabsigh A, Spratt DE, Teply BA, Tward J, Shead DA, Freedman-Cass DA. NCCN Guidelines Insights: Prostate Cancer, Version 1.2021. J Natl Compr Canc Netw. 2021 Feb;19(2):134–143.
  187. Ma TM, Gafita A, Shabsovich D, Juarez J, Grogan TR, Thin P, Armstrong W, Sonni I, Nguyen K, Lok V, Reiter RE, Rettig MB, Steinberg ML, Kupelian PA, Yang DD, Muralidhar V, Chu C, Feng F, Savjani R, Deng J, Parikh NR, Nickols NG, Elashoff D, Czernin J, Calais J, Kishan AU. Identifying the Best Candidates for PSMA PET/CT as the Primary Staging Approach Among Men with High-risk Prostate Cancer and Negative Conventional Imaging. Eur Urol Oncol. 2022 Feb;5(1):100–103.
  188. Murad JP, Tilakawardane D, Park AK, Lopez LS, Young CA, Gibson J, Yamaguchi Y, Lee HJ, Kennewick KT, Gittins BJ, Chang WC, Tran CP, Martinez C, Wu AM, Reiter RE, Dorff TB, Forman SJ, Priceman SJ. Pre-conditioning Modifies the TME to Enhance Solid Tumor CAR T Cell Efficacy and Endogenous Protective Immunity. Mol Ther. 2021 Jul;29(7):2335–2349.
  189. Cipollari S, Jamshidi N, Du L, Sung K, Huang D, Margolis DJ, Huang J, Reiter RE, Kuo MD. Tissue Clearing Techniques for Three-Dimensional Optical Imaging of Intact Human Prostate and Correlations with Multi-Parametric MRI. Prostate. 2021 Jun;81(9):521–529.
  190. Raman AG, Sarma KV, Raman SS, Priester AM, Mirak SA, Riskin-Jones HH, Dhinagar N, Speier W, Felker E, Sisk AE, Lu D, Kinnaird A, Reiter RE, Marks LS, Arnold CW. Optimizing Spatial Biopsy Sampling for the Detection of Prostate Cancer. J Urol. 2021 Sep;206(3):595–603.
  191. Philipson RG, Romero T, Wong JK, Stish BJ, Dess RT, Spratt DE, Pilar A, Reddy C, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Braccioforte M, Tran PT, Martin S, Martinez-Monge R, Krauss DJ, Abu-Isa EI, Valle L, Chong N, Pisansky TM, Choo CR, Song DY, Greco S, Deville C, McNutt T, DeWeese TL, Ross AE, Ciezki JP, Tilki D, Karnes RJ, Klein EA, Tosoian JJ, Boutros PC, Nickols NG, Bhat P, Shabsovich D, Juarez JE, Kupelian PA, Rettig MB, Berlin A, Tward JD, Davis BJ, Reiter RE, Steinberg ML, Elashoff D, Horwitz EM, Tendulkar RD, Kishan AU. Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer. Eur Urol. 2021 Aug;80(2):142–146.
  192. Kishan AU, Karnes RJ, Romero T, Wong JK, Motterle G, Tosoian JJ, Trock BJ, Klein EA, Stish BJ, Dess RT, Spratt DE, Pilar A, Reddy C, Levin-Epstein R, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Braccioforte M, Huland H, Tran PT, Martin S, Martínez-Monge R, Krauss DJ, Abu-Isa EI, Alam R, Schwen Z, Chang AJ, Pisansky TM, Choo R, Song DY, Greco S, Deville C, McNutt T, DeWeese TL, Ross AE, Ciezki JP, Boutros PC, Nickols NG, Bhat P, Shabsovich D, Juarez JE, Chong N, Kupelian PA, D’Amico AV, Rettig MB, Berlin A, Tward JD, Davis BJ, Reiter RE, Steinberg ML, Elashoff D, Horwitz EM, Tendulkar RD, Tilki D. Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features. JAMA Netw Open. 2021 Jul;4(7):e2115312.
  193. Jiang T, Markovic D, Patel J, Juarez JE, Ma TM, Shabsovich D, Nickols NG, Reiter RE, Elashoff D, Rettig MB, Zaorsky NG, Spratt DE, Kishan AU. Radiation Therapy Dose and Androgen Deprivation Therapy in Localized Prostate Cancer: A Meta-Regression of 5-Year Outcomes in Phase III Randomized Controlled Trials. Prostate Cancer Prostatic Dis. 2022 Mar;25(1):126–128.
  194. Hope TA, Eiber M, Armstrong WR, Juarez R, Murthy V, Lawhn-Heath C, Behr SC, Zhang L, Barbato F, Ceci F, Farolfi A, Schwarzenböck SM, Unterrainer M, Zacho HD, Nguyen HG, Cooperberg MR, Carroll PR, Reiter RE, Holden S, Herrmann K, Zhu S, Fendler WP, Czernin J, Calais J. Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial. JAMA Oncol. 2021 Nov;7(11):1635–1642.
  195. Aggarwal R, Rydzewski NR, Zhang L, Foye A, Kim W, Helzer KT, Bakhtiar H, Chang SL, Perry MD, Gleave M, Reiter RE, Huang J, Evans CP, Alumkal JJ, Lang JM, Yu M, Quigley DA, Sjöström M, Small EJ, Feng FY, Zhao SG. Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate Cancer. JAMA Oncol. 2021 Nov;7(11):1644–1652.
  196. Cipollari S, Jamshidi N, Du L, Sung K, Huang D, Margolis DJ, Huang J, Reiter RE, Kuo MD. Tissue Clearing Techniques for Three-Dimensional Optical Imaging of Intact Human Prostate and Correlations with Multi-Parametric MRI. Prostate. 2021 Dec;81(16):1450.
  197. Sonni I, Felker ER, Lenis AT, Sisk AE, Bahri S, Allen-Auerbach M, Armstrong WR, Suvannarerg V, Tubtawee T, Grogan T, Elashoff D, Eiber M, Raman SS, Czernin J, Reiter RE, Calais J. Head-to-Head Comparison of 68Ga-PSMA-11 PET/CT and mpMRI with a Histopathology Gold Standard in the Detection, Intraprostatic Localization, and Determination of Local Extension of Primary Prostate Cancer. J Nucl Med. 2022 Jun;63(6):847–854.
  198. Liu Y, Zheng H, Liang Z, Miao Q, Brisbane WG, Marks LS, Raman SS, Reiter RE, Yang G, Sung K. Textured-Based Deep Learning in Prostate Cancer Classification with 3T Multiparametric MRI: Comparison with PI-RADS-Based Classification. Diagnostics (Basel). 2021 Sep 28;11(10):1785.
  199. Kinnaird A, Yerram NK, O’Connor L, Brisbane W, Sharma V, Chuang R, Jayadevan R, Ahdoot M, Daneshvar M, Priester A, Delfin M, Tran E, Barsa DE, Sisk A, Reiter RE, Felker E, Raman S, Kwan L, Choyke PL, Merino MJ, Wood BJ, Turkbey B, Pinto PA, Marks LS. Magnetic Resonance Imaging-Guided Biopsy in Active Surveillance of Prostate Cancer.J Urol. 2022 Apr;207(4):823–831.
  200. Dominique G, Brisbane WG, Reiter RE. The Utility of Prostate MRI Within Active Surveillance: Description of the Evidence. World J Urol. 2022 Jan;40(1):71–77.
  201. Xiang M, Ma TM, Savjani R, Pollom EL, Karnes RJ, Grogan T, Wong JK, Motterle G, Tosoian JJ, Trock BJ, Klein EA, Stish BJ, Dess RT, Spratt DE, Pilar A, Reddy C, Levin-Epstein R, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Huland H, Tran PT, Martin S, Martinez-Monge R, Krauss DJ, Abu-Isa EI, Alam R, Schwen Z, Pisansky TM, Choo CR, Song DY, Greco S, Deville C, McNutt T, DeWeese TL, Ross AE, Ciezki JP, Boutros PC, Nickols NG, Bhat P, Shabsovich D, Juarez JE, Chong N, Kupelian PA, Rettig MB, Zaorsky NG, Berlin A, Tward JD, Davis BJ, Reiter RE, Steinberg ML, Elashoff D, Horwitz EM, Tendulkar RD, Tilki D, Czernin J, Gafita A, Romero T, Calais J, Kishan AU. Performance of a PSMA PET/CT-Derived Risk-Stratification Tool for High-Risk and Very High-Risk Prostate Cancer. JAMA Netw Open. 2021 Dec;4(12):e2138550.
  202. Kishan AU, Steigler A, Denham JW, Zapatero A, Guerrero A, Joseph D, Maldonado X, Wong JK, Stish BJ, Dess RT, Spratt DE, Pilar A, Reddy C, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Tran PT, Martin S, Martinez-Monge R, Krauss DJ, Abu-Isa EI, Pisansky TM, Choo CR, Song DY, Greco S, Deville C, McNutt T, DeWeese TL, Ross AE, Ciezki JP, Tilki D, Karnes RJ, Tosoian JJ, Nickols NG, Bhat P, Shabsovich D, Juarez JE, Jiang T, Ma TM, Xiang M, Philipson R, Chang A, Kupelian PA, Rettig MB, Feng FY, Berlin A, Tward JD, Davis BJ, Reiter RE, Steinberg ML, Elashoff D, Boutros PC, Horwitz EM, Tendulkar RD, Spratt DE, Romero T. Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer: A Patient-Level Data Analysis of 3 Cohorts. JAMA Oncol. 2022 Mar;8(3):e216871.
  203. Kishan AU, Sun Y, Hartman H, Pisansky TM, Bolla M, Neven A, Steigler A, Denham JW, Feng FY, Zapatero A, Armstrong JG, Nabid A, Carrier N, Souhami L, Dunne MT, Efstathiou JA, Sandler HM, Guerrero A, Joseph D, Maingon P, de Reijke TM, Maldonado X, Ma TM, Romero T, Wang X, Rettig MB, Reiter RE, Zaorsky NG, Steinberg ML, Nickols NG, Jia AY, Garcia JA, Spratt DE; MARCAP Consortium group. Androgen Deprivation Therapy Use and Duration With Definitive Radiotherapy for Localized Prostate Cancer: An Individual Patient Data Meta-analysis. Lancet Oncol. 2022 Feb;23(2):304–316.
  204. Patel NA, Reiter RE. Impact of a Novel Molecular Imaging Modality, Prostate-Specific Membrane Antigen Positron Emission Tomography, on the Management of Prostate Cancer. J Clin Oncol. 2022 May;40(13):1497–1499.
  205. Turco F, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke C, Clarke N, Davis ID, de Bono J, Duran I, Eeles R, Efstathiou E, Efstathiou J, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, George D, Gleave M, Halabi S, Heinrich D, Higano C, Hofman MS, Hussain M, James N, Jones R, Kanesvaran R, Khauli RB, Klotz L, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ost P, O’Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin M, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Shore N, Skoneczna I, Small E, Smith M, Soule H, Spratt D, Sternberg CN, Suzuki H, Sweeney C, Sydes M, Taplin ME, Tilki D, Tombal B, Türkeri L, Uemura H, van Oort I, Yamoah K, Ye D, Zapatero A, Gillessen S, Omlin A. What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. Eur Urol. 2022 Jul;82(1):6–11.
  206. Turco F, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke C, Clarke N, Davis ID, de Bono J, Duran I, Eeles R, Efstathiou E, Efstathiou J, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, George D, Gleave M, Halabi S, Heinrich D, Higano C, Hofman MS, Hussain M, James N, Jones R, Kanesvaran R, Khauli RB, Klotz L, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ost P, O’Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin M, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Shore N, Skoneczna I, Small E, Smith M, Soule H, Spratt D, Sternberg CN, Suzuki H, Sweeney C, Sydes M, Taplin ME, Tilki D, Tombal B, Türkeri L, Uemura H, van Oort I, Yamoah K, Ye D, Zapatero A, Gillessen S, Omlin A. Corrigendum to “What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic.” Eur Urol. 2022 Jul;82(1):e18–e19.
  207. Kishan AU, Wang X, Sun Y, Romero T, Michalski JM, Ma TM, Feng FY, Sandler HM, Bolla M, Maingon P, De Reijke T, Neven A, Steigler A, Denham JW, Joseph D, Nabid A, Carrier N, Souhami L, Sydes MR, Dearnaley DP, Syndikus I, Tree AC, Incrocci L, Heemsbergen WD, Pos FJ, Zapatero A, Efstathiou JA, Guerrero A, Alvarez A, San-Segundo CG, Maldonado X, Xiang M, Rettig MB, Reiter RE, Zaorsky NG, Ong WL, Dess RT, Steinberg ML, Nickols NG, Roy S, Garcia JA, Spratt DE; MARCAP Consortium. High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer. Eur Urol. 2022 Jul;82(1):106–114.
  208. Khoo A, Liu LY, Sadun TY, Salmasi A, Pooli A, Felker E, Houlahan KE, Ignatchenko V, Raman SS, Sisk AE Jr, Reiter RE, Boutros PC, Kislinger T. Prostate Cancer Multiparametric MRI Visibility Is a Tumor-Intrinsic Phenomenon. J Hematol Oncol. 2022 May;15(1):48.
  209. Shirk JD, Reiter R, Wallen EM, Pak R, Ahlering T, Badani KK, Porter JR. Effect of 3D Virtual Reality Models for Surgical Planning of Robotic Prostatectomy on Trifecta Outcomes: A Randomized Clinical Trial. J Urol. 2022 Sep;208(3):618–625.
  210. Joy A, Nagarajan R, Saucedo A, Iqbal Z, Sarma MK, Wilson N, Felker E, Reiter RE, Raman SS, Thomas MA. Dictionary Learning Compressed Sensing Reconstruction: Pilot Validation of Accelerated Echo Planar J-resolved Spectroscopic Imaging in Prostate Cancer. MAGMA. 2022 Aug;35(4):667–682.
  211. Ma TM, Chu FI, Sandler H, Feng FY, Efstathiou JA, Jones CU, Roach M III, Rosenthal SA, Pisansky T, Michalski JM, Bolla M, de Reijke TM, Maingon P, Neven A, Denham J, Steigler A, Joseph D, Nabid A, Souhami L, Carrier N, Incrocci L, Heemsbergen W, Pos FJ, Sydes MR, Dearnaley DP, Tree AC, Syndikus I, Hall E, Cruickshank C, Malone S, Roy S, Sun Y, Zaorsky NG, Nickols NG, Reiter RE, Rettig MB, Steinberg ML, Reddy VK, Xiang M, Romero T, Spratt DE, Kishan AU; MARCAP Consortium Investigators. Local Failure Events in Prostate Cancer Treated with Radiotherapy: LEVIATHAN Analysis of 18 Trials. Eur Urol. 2022 Nov;82(5):487–498.
  212. Ma TM, Ballas LK, Wilhalme H, Sachdeva A, Chong N, Sharma S, Yang T, Basehart V, Reiter RE, Saigal C, Chamie K, Litwin MS, Rettig MB, Nickols NG, Yoon SM, Smith L, Gao Y, Steinberg ML, Cao M, Kishan AU. Quality-of-Life Outcomes and Toxicity Profile Among Patients With Localized Prostate Cancer After Radical Prostatectomy Treated With SBRT: The SCIMITAR Trial. Int J Radiat Oncol Biol Phys. 2022 Aug 23.
  213. Westbrook TC, Guan X, Rodansky E, Flores D, Liu CJ, Udager AM, Patel RA, Haffner MC, Hu YM, Sun D, Beer TM, Foye A, Aggarwal R, Quigley DA, Youngren JF, Ryan CJ, Gleave M, Wang Y, Huang J, Coleman I, Morrissey C, Nelson PS, Evans CP, Lara P, Reiter RE, Witte O, Rettig M, Wong CK, Weinstein AS, Uzunangelov V, Stuart JM, Thomas GV, Feng FY, Small EJ, Yates JA, Xia Z, Alumkal JJ. Transcriptional Profiling of Matched Patient Biopsies Clarifies Molecular Determinants of Enzalutamide-Induced Lineage Plasticity. Nat Commun. 2022 Sep;13(1):5345.
  214. Patel SA, Ma TM, Wong JK, Stish BJ, Dess RT, Pilar A, Reddy C, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Tran PT, Krauss DJ, Abu-Isa EI, Pisansky TM, Choo CR, Song DY, Greco S, Deville C, DeWeese TL, Tilki D, Ciezki JP, Karnes RJ, Nickols NG, Rettig MB, Feng FY, Berlin A, Tward JD, Davis BJ, Reiter RE, Boutros PC, Romero T, Horwitz EM, Tendulkar RD, Steinberg ML, Spratt DE, Xiang M, Kishan AU. External Beam Radiation Therapy With or Without Brachytherapy Boost in Very-High-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2022 Sep 28.
  215. Sjöström M, Zhao SG, Levy S, Zhang M, Ning Y, Shrestha R, Lundberg A, Herberts C, Foye A, Aggarwal R, Hua JT, Li H, Bergamaschi A, Maurice-Dror C, Maheshwari A, Chen S, Ng SWS, Ye W, Petricca J, Fraser M, Chesner L, Perry MD, Moreno-Rodriguez T, Chen WS, Alumkal JJ, Chou J, Morgans AK, Beer TM, Thomas GV, Gleave M, Lloyd P, Phillips T, McCarthy E, Haffner MC, Zoubeidi A, Annala M, Reiter RE, Rettig MB, Witte ON, Fong L, Bose R, Huang FW, Luo J, Bjartell A, Lang JM, Mahajan NP, Lara PN, Evans CP, Tran PT, Posadas EM, He C, Cui XL, Huang J, Zwart W, Gilbert LA, Maher CA, Boutros PC, Chi KN, Ashworth A, Small EJ, He HH, Wyatt AW, Quigley DA, Feng FY. The 5-Hydroxymethylcytosine Landscape of Prostate Cancer. Cancer Res. 2022 Oct 17.

Book Chapters

  1. Reiter RE, Zbar B, Linehan WM. Molecular genetic studies of renal cell carcinoma: potential biologic and clinical significance for genitourinary malignancy. In: Walsh PC, Retik AB, Stamey TA, Vaughan ED (eds). Campbell’s Urology (Update 7). WB Saunders, Philadelphia; 1993.
  2. Reiter RE, Scardino PT, Miles B. Salvage radical prostatectomy for local recurrence of prostate cancer after radiation therapy. In: Vogelzang N, Scardino PT, Shipley W, Coffey D (eds). Comprehensive Textbook of Genitourinary Oncology. Williams & Wilkins; 1995/2000 (update).
  3. Reiter RE, Sawyers CL. Xenograft models and the molecular biology of human prostate cancer. In: Isaacs WB, Chung L (eds). Prostate Cancer. 2001.
  4. Reiter RE, DeKernion JB. Epidemiology, Etiology and Prevention of Prostate Cancer. In: Walsh PC, Retik AB, Stamey TA, Vaughan ED (eds). Campbell’s Urology. WB Saunders, Philadelphia; 2002: 3003–3024.
  5. Chin J, Reiter RE. Genetic Alterations in Prostate Cancer. Current Urology Reports. 2004;5:157.
  6. Reiter RE, Kibel A. Molecular Biology of Urologic Cancer. In: Campbell’s Urology. WB Saunders; 2006.
  7. Lam J, Reiter RE. Tissue Markers for Prostate Cancer. In: Comprehensive Prostate Cancer Textbook. 2006.
  8. Reiter RE. Cancer Stem Cells in Prostate Cancer. In: Klein E (ed). Prostate Cancer. 2011.

Scientific Editorials

  1. Reiter RE. Editorial comment: The prognostic value of pretreatment expression of androgen receptor and bcl-2 in hormonally treated prostate cancer patients. Journal of Urology. 1997;158:1884.
  2. Reiter RE. Editorial comment: Adenocarcinoma of the urachus and bladder expresses a unique colonic epithelial epitope: an immunohistochemical study. Journal of Urology. 1997;158:1722.
  3. Reiter RE. Editorial comment: Retrospective comparison of radical retropubic prostatectomy and I125 brachytherapy for localized prostate cancer. Journal of Urology. 1999;161:1215.
  4. Reiter RE. Editorial comment: Prostate-specific antigen nadir achieved by men apparently cured of prostate cancer by radiotherapy. Journal of Urology. 1999;161:1203.
  5. Reiter RE. Robotically assisted laparoscopic prostatectomy: getting started. The American Journal of Urology.2005;3:1-4.
  6. Reiter RE, Shurtlef B. What are the operating characteristics of PSA for screening prostate cancer? Nature Clinical Practice Urology. 2006;2:74-75.

Published Abstracts (through 2004)

  • Gnarra JR, Latif F, Tory K, Anglard P, Reiter RE, Trahan E, Liu S, Lerman M, Zbar B, Linehan WM.Molecular characterization of tumor suppressor genes involved in human renal cell carcinoma. Journal of Urology.1992;147(Suppl):319A.
  • Reiter RE, Gnarra JR, Anglard P, Liu S, Linehan WM. Chromosome 17p deletions and p53 mutations in advanced renal cell carcinoma. Journal of Urology. 1993;149(Suppl):462A.
  • Walther MM, Alexander RB, Reiter RE, Choyke PL, Linehan WM. Nephron sparing surgery in patients with hereditary and sporadic renal cell carcinoma. Journal of Urology. 1994;151(Suppl):317A.
  • Reiter RE, Wheeler T, Carlton CE, Scardino PT, Miles BJ. Radical perineal vs. retropubic prostatectomy in clinical T1c prostate cancer: a pathologic comparison. Journal of Urology. 1995;153(Suppl):501A.
  • Reiter RE, Klein K, Sawyers C, Witte ON. Representational difference analysis of human androgen-independent prostate cancer. Proc Am Assoc Cancer Res. 1996;37:246.
  • Klein K, Reiter RE, Belldegrun A, Sawyers C. Development of a unique model for the propagation and study of human prostate tumors in vivo. Proc Am Assoc Cancer Res. 1996;37:71.
  • Walther MM, Reiter RE, Keiser HR, Choyke P, Zbar B, Linehan WM. Pheochromocytoma in von Hippel-Lindau disease: clinical and genetic characterization. Journal of Urology. 1996;155(Suppl):499A.
  • Reiter RE, Magi-Galuzzi C, Hemmatti H, Sawyers C, Loda M, Witte ON. Two genes upregulated in androgen-independent prostate cancer are also selectively expressed in the basal cells of normal prostate epithelium. Journal of Urology. 1997;157(Suppl):269A.
  • Redula J, Klein K, Reiter R, Witte ON, Sawyers C. Progression of human prostate cancer to androgen independence in immunodeficient SCID mice. Proc Am Assoc Cancer Res. 1997;38.
  • Craft N, Tran C, Chhor C, Stevenson S, Belldegrun A, Witte ON, Reiter RE, Sawyers CL. Metastatic and hormone dependent characteristics of the LAPC series of prostate cancer xenografts. Proc Am Assoc Cancer Res.1998;39.
  • Whang Y, Wu X, Tran C, Reiter RE, Vessella R, Sawyers C. Frequent transcriptional silencing of the tumor suppressor PTEN/MMAC1 gene in prostate cancer xenografts. Proc Am Assoc Cancer Res. 1998;39.
  • Gu Z, Shintaku P, Yamashiro J, Said J, Reiter RE. Monoclonal antibodies against prostate stem cell antigen (PSCA) detect high levels of PSCA expression in prostate cancer bone metastases. Journal of Urology.1999;161(Suppl):477A.
  • Reiter RE, Yamashiro J, Sawyers C, Loda M, Witte ON. A type II transmembrane glycoprotein associated with osteogenesis can accelerate androgen-independent prostate cancer progression in vivo. Journal of Urology.1999;161(Suppl):488A.
  • Rauch M, Schrage M, Dorey F, deKernion JB, Said J, Reiter RE. Low p27 protein expression independently predicts poor disease-free survival in patients with positive surgical margins following radical prostatectomy.Journal of Urology. 1999;161(Suppl):924A.
  • Brandeis JM, Litwin MS, Nurnison CM, Reiter RE. Early quality of life outcomes in men receiving brachytherapy or radical prostatectomy. Journal of Urology. 1999;161(Suppl):1375A.
  • Amara N, Gu Z, Salur G, Schrage M, Thomas G, Said J, Reiter RE. Prostate stem cell antigen (PSCA) is overexpressed in a majority of bladder cancers. Eur Urol. 2000;37(Suppl 2):354A.
  • Amara N, Gu Z, Dorey F, Reiter RE. Monoclonal antibodies against prostate stem cell antigen inhibit prostate cancer tumor formation in SCID mice. Eur Urol. 2000;37(Suppl 2):420A.
  • Brandeis J, Chand I, Kwan L, Dougherty S, Reiter RE, Litwin MS. Pretreatment quality of life in men with early stage prostate cancer. Journal of Urology. 2000;163(Suppl):68A.
  • Watabe T, Lin M, Donjacour A, Cunha G, Witte ON, Reiter RE. The 9kb prostate stem cell antigen promoter directs reporter gene expression to the ductal tips of prostate in transgenic mice. Journal of Urology.2000;163(Suppl):132A.
  • Amara N, Thomas G, Said J, Reiter RE. Prostate stem cell antigen is overexpressed in a majority of bladder cancers. Journal of Urology. 2000;163(Suppl):552A.
  • Thomas G, Schrage M, Dorey M, Said J, Reiter RE. Correlation of p27 expression in preoperative prostate needle biopsy and subsequent radical prostatectomy. Journal of Urology. 2000;163(Suppl):810A.
  • Brandeis J, Chand I, Kwan L, Dougherty S, Reiter RE, Litwin MS. A prospective study of the short term effects of radical prostatectomy vs. brachytherapy on quality of life. Journal of Urology. 2000;163(Suppl):1267A.
  • Palapattu G, Gu Z, Saffran D, Kono E, Yamshiro J, Jakobovits A, Reiter RE. Monoclonal antibody against prostate stem cell antigen inhibits prostate cancer growth and metastasis in a murine xenograft model of prostate cancer. Journal of Urology. 2001;165(Suppl):188A.
  • Palapattu G, Amara N, Gu Z, Thomas G, Yamashiro J, Dorey F, Said J, Reiter RE. Prostate stem cell antigen is overexpressed in human transitional cell carcinoma. Journal of Urology. 2001;165(Suppl):457A.
  • Tran C, Lin C, Yamashiro J, Reiter RE. Prostate stem cell antigen is a marker of an intermediate progenitor cell population in human prostate epithelial cells. Journal of Urology. 2001;165(Suppl):578A.
  • DePrimo S, Brown P, Brooks JD, Nelson JB, Reiter RE. Microarray analysis of the transcriptional programs activated by exposure of prostate cancer cells to androgen. Journal of Urology. 2001;165(Suppl):583A.
  • Saffran DC, Raitano AB, Hubert RS, Witte ON, Reiter RE, Jakobovits A. Anti-PSCA monoclonal antibodies inhibit tumor growth and prolong survival of mice bearing human prostate cancer xenografts. Proc Am Assoc Cancer Res. 2001;42:4543A.
  • Litwin MS, Brandeis J, Chand I, Kwan L, Dougherty S, Reiter RE. Quality of life in the year following brachytherapy, external beam radiation or prostatectomy. Journal of Urology. 2002;167(Suppl):122A.
  • Jain A, Carey M, Reiter RE. A tissue-specific enhancer directs the androgen responsive regulation of prostate stem cell antigen. Journal of Urology. 2002;167(Suppl):122A.
  • Gu Z, Yamashiro J, Kono E, Reiter RE. A monoclonal antibody against PSCA inhibits prostate cancer growth and metastasis through a direct effect on tumor cells. Journal of Urology. 2003;169(Suppl):348A.
  • Reiter RE, Seligson D, Said J. Trefoil factor 3 is overexpressed in prostate cancer. Journal of Urology.2003;169(Suppl):643A.
  • Garraway IP, Tran C, Reiter RE. Development of a novel mouse model for induction and imaging of bladder cancer. Journal of Urology. 2003;169(Suppl):735A.
  • Freedland S, Degregorio F, Csathy GC, Dorey F, Reiter RE, Aronson WJ. Preoperative p27 status is an independent predictor of PSA failure following radical prostatectomy. Journal of Urology. 2003;169(Suppl):1851A.
  • Reiter RE, Rubin M, Loda M, Gu Z. Reg IV: A promising marker of hormone refractory metastatic prostate cancer. Journal of Urology. 2004;171(Suppl):590A.
  • Han K, Seligson D, Liu X, Horvath S, Shintaku PI, Thomas G, Said JW, Reiter RE. Prostate stem cell antigen expression is associated with Gleason score, seminal vesicle invasion, and capsular invasion in prostate cancer.Journal of Urology. 2004;171(Suppl):860A.
  • Reiter RE, Wu A, Sherman M, Gu Z. Recombinant anti-PSCA antibodies inhibit prostate and bladder cancer growth in xenograft models and are superior to parental murine antibody. Journal of Urology.2004;171(Suppl):1091A.

Office Address: Center for the Health Sciences, Room 66-128, 10833 Le Conte Ave., Los Angeles, CA 90095-1738
Office Telephone: (310) 794-7224
Fax: (310) 206-5343
Lab: (310) 206-5942
Work Email: [email protected]